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BSA: Bovine serum albumin 
CA-074: (L-3-trans-(Propylcarbamyl)oxirane-2-carbonyl)-L-isoleucyl-L-proline 
Cath-D: cathepsin D 
CM: Conditioned medium  
C-terminal : carboxy-terminal 
Cyst C: cystatin C 
Da: Dalton 
DMEM : Dulbecco's Modified Eagle Medium 




EF: eluted fraction  
FCS: fetal calf serum 
GST: glutathione S-transferase 
h: hour 
HCl: Hydrochloric acid 
HPLC: High-performance liquid chromatography 
IgG: Immunoglobulin G  
IP: immunoprecipitation 
iTRAQ : Isotope Tags for Relative and Absolute Quantification  
KDa: kiloDalton          
LC-MS/MS: Liquid chromatography coupled to tandem mass spectrometry 
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Luc: luciferase  
MEF: mouse embryonic fibroblast  
min: minute 
N-terminal : amino-terminal 
Opti-MEM : Dulbecco's Modified Eagle Medium  
Pepst.: Pepstatin A 
Pro-cath-D: procathepsin D 
SDS-PAGE: SDS-PolyAcrylamide Gel Electrophoresis 
siRNA: silencing RNA 








The aspartic protease cathepsin D, a poor prognostic indicator of breast cancer, is 
abundantly secreted as procathepsin D by human breast cancer cells and self-
activates at low pH in vitro, giving rise to catalytically-active cathepsin D. Due to a 
lower extracellular pH in tumor microenvironments compared to normal tissues, 
cathepsin D may cleave pathophysiological substrates contributing to cancer 
progression. Here, we show by yeast two-hybrid and degradomics analyses that 
cystatin C, the most potent natural secreted inhibitor of cysteine cathepsins, both 
binds to and is a substrate of extracellular procathepsin D. The amount of cystatin C 
in the extracellular environment is reduced in the secretome of mouse embryonic 
fibroblasts stably transfected with human cathepsin D. Cathepsin D extensively 
cleaved cystatin C in vitro at low pH. Cathepsin D secreted by breast cancer cells 
also processed cystatin C at the pericellular pH of tumors so enhancing extracellular 
proteolytic activity of cysteine cathepsins. Thus, tumor derived cathepsin D assists 
breast cancer progression by reducing cystatin C activity, which in turn enhances 
cysteine cathepsin proteolytic activity, revealing a new link between protease classes 
in the protease web. 
 










Human cathepsin D is a ubiquitous, lysosomal, aspartic endoproteinase that is 
proteolytically active at low pH. Cathepsin D is overproduced and abundantly 
secreted by human epithelial breast cancer cells (1, 2) with expression levels in 
breast cancer correlating with poor prognosis (3, 4). Cathepsin D affects both cancer 
and stromal cells in the tumor microenvironment by increasing the proliferation of 
cancer cells (1, 5, 6), stimulating fibroblast outgrowth (7, 8), angiogenesis (5, 9), and 
metastasis (10). However, little is known of the molecular mechanisms involved or its 
substrates in these processes.   
Human cathepsin D is synthesized as a 52-kDa precursor that is converted in 
the endosomes to an active, 48-kDa single-chain intermediate, and then to the fully 
active mature protease in the lysosomes. Mature human cathepsin D is composed of 
a 34-kDa heavy chain and a 14-kDa light chain. Its catalytic site includes two critical 
aspartic residues, residues 33 on the 14-kDa chain and 231 on the 34-kDa chain. 
The over-production of cathepsin D by breast cancer cells leads to hypersecretion of 
the 52-kDa procathepsin D into the extracellular environment (1, 2). Purified 52-kDa 
procathepsin D auto-activates in acidic conditions giving rise to a catalytically active 
51-kDa pseudo-cathepsin D, which retains the 18 residues (27-44) of the pro-
segment (11). While the extracellular environment is more acidic in tumors than in the 
corresponding normal tissues (12-14), the question is whether it is sufficiently acidic 
for procathepsin D to cleave its pathophysiological substrates. If so, the identification 
of these substrates will be important for the mechanistic understanding of the role of 
this protease in cancer.  
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We show that procathepsin D secreted by breast cancer cells binds to cystatin 
C and specifically hydrolyses this cysteine protease (family C1) inhibitor. Cysteine 
cathepsins promote the proliferation, invasion, and metastasis of cancer cells (15, 16) 
suggesting a new unexplored link in the protease web (17, 18). Using a degradomics 
approach known as terminal amine isotopic labelling of substrates (TAILS) (19, 20), 
we found that the amount of cystatin C in the extracellular environment is reduced in 
a cathepsin D-dependent manner in the secretome of mouse embryonic fibroblasts 
(MEFs) derived from cathepsin D knock-out mice stably transfected with human 
cathepsin D compared to cathepsin D-/- MEFs. In particular, we show that 
procathepsin D secreted by breast cancer cells contributes to the protease web in the 
acidic tumor microenvironment by specific cleavages in cystatin C, thereby increasing 




MATERIALS AND METHODS 
Yeast two-hybrid assay 
Human cath-D was fused with the LexA DNA-binding domain of the pMW101 vector. 
A cDNA library derived from normal breast tissue was cloned into the galactosidase-
inducible pYESTrp2 vector (Invitrogen) containing a B42 activating domain. The 
yeast two-hybrid screen was performed as described previously (8).  
 
Plasmids 
Human pcDNA3.1(-)cathepsin D expression plasmid has previously been described 
(8). The full-length human cystatin C was sub-cloned from the pUC18 cystatin C 
plasmid into the HindIII and EcoR1 sites of the pcDNA3.1(+) vector (Invitrogen) to 
make pcDNA3.1(+)cystatin C. For GST pull-down, pGEX-4T-2cystatin C was 
generated by inserting PCR-amplified cDNA encoding human cystatin C (1-146) from 
pcDNA3.1(+)cystatin C into pGEX-4T-2 that had been digested by EcoRI and XhoI. 
 
GST pull-down assay 
[35S]methionine-labeled procathepsin D was obtained by transcription and translation 
using the TNTT7-coupled reticulocyte lysate system (Promega). GST and GST-
cystatin C fusion proteins were produced in Escherichia coli B strain BL21 by 
incubation with isopropyl-1-thio--D-galactopyranoside (1 mM) for 3 h at 37°C. The 
GST fusion proteins were purified on glutathione-Sepharose beads (Amersham 
Biosciences). For pull-down assays, 20 µl bed volume of glutathione-Sepharose 
beads with immobilized GST fusion proteins were incubated overnight at 4°C with 
[35S]methionine-labeled proteins in 500 µl PDB buffer (20 mM HEPES-KOH (pH 7.9), 
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10% glycerol, 100 mM KCl, 5 mM MgCl2, 0.2 mM EDTA, 1 mM DTT, 0.2 mM 
phenylmethylsulfonylfluoride) containing 15 mg/ml BSA and 0.1% Tween 20. The 
beads were washed four times with 500 µl PDB buffer, and the eluted proteins were 
resolved by 15% SDS-PAGE, stained with Coomassie blue, and exposed to X-ray 
film.  
 
Secretome preparation  
Cathepsin D-/- immortalized MEFs stably transfected with empty vector (CD55-/-
SV40) or the cath-D expression vector encoding human pre-procathepsin D (CD55-/-
cath-D) were prepared as previously described (7). MEF cells (6 T175 flasks per 
condition) grown to 80% confluence were washed extensively with phenol red-free, 
serum-free medium to remove serum proteins and grown overnight in phenol red-
free, serum-free medium. Samples of conditioned medium were immediately treated 
with protease inhibitors (1 mM EDTA, protease inhibitor cocktail (Complete; Roche 
Applied Science)), clarified by centrifugation (5 min, 500 g; 30 min, 8,000 g) and 
filtered (0.45 µM). Conditioned medium proteins in 50 mM Hepes, pH 7.5 were then 
concentrated to 2 mg/ml by passage through Amicon filters (3 kDa cut-off, Millipore). 
 
Enrichment and mass spectrometric analysis of protein N-termini 
Protein N-terminal peptides were enriched using Terminal Amine Isotope Labeling of 
Substrates (TAILS) as described (19) using the option for isotopic labeling of proteins 
with iTRAQ reagents. Peptides were pre-fractionated by strong cation exchange 
chromatography and analysed by LC-MS/MS (QSTAR XL, Applied Biosystems). 
Peptides were identified at the 95% confidence level from the human 
UniProtKB/Swissprot protein database (release date) using two search engines, 
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MASCOT v2.3 (Matrix Science) and X!TANDEM (21), in conjunction with 
PeptideProphet (19) as implemented in the Trans Proteomic Pipeline v4.3. Search 
parameters were: Semi-ArgC peptides with up to two missed cleavages, 0.4 Da 
precursor ion mass tolerance, 0.4 Da fragment ion mass tolerance, 
carboxyamidomethylation of cysteine residues (+57.02 Da) and iTRAQ-labeling of 
lysine e-amines (+144.10 Da) as fixed modifications, and peptide N-terminal iTRAQ 
labelling (+144.10 Da), peptide N-terminal acetylation (+42.01 Da) and Met oxidation 
(+15.99 Da) as variable modification. Results from both searches were combined 
using an in-house software script (22), requiring peptides to have an Arg at their C-
terminus and showing an iTRAQ reporter ion intensity of >30 in at least one of the 
compared channels. N-terminal peptides with significant changes between two 
conditions were determined by calculation the log2 of the intensity rations, correction 
for the mean of all ratios, and application of a 3-fold change cut-off (mean-corrected 
log2>1.58 or <-1.58). The data associated with this manuscript may be downloaded 
from the ProteomeCommons.org Tranche network using the following hash: 
yYqDvOHCujSd0Ng/7rrjUz9E4f4ru5BO1CMElAKbaYTnVucBssF7vP9jBu8PhzZktFjT
OwzBpttpDPOGKsl4j+KdRTgAAAAAAAADiw==. The passcode for downloading the 
data is: CDsecretomeTAILS. 
 
siRNA transfection 
Duplexes of 21-nucleotide human cathepsin D (target sequence 
AAGCUGGUGGACCAGAACAU (8)) or firefly luciferase (Luc) siRNA (target 
sequence AACGUACGCGGAAUACUUCGA) were synthesized by MWG Biotech 
S.A. MCF-7 cells were transiently transfected with 5 µg human cathepsin D or Luc 
siRNAs using Oligofectamine (Invitrogen). 48 h post-transfection, the culture medium 
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was then changed and conditioned medium was prepared by incubating the siRNA-
transfected cells in FCS-free DMEM buffered with 50 mM Hepes (pH 7) for 24 h.  
 
Transfection, immunoprecipitation, immunoblotting and purification of 
cathepsin D and cystatin C 
Cells were cultured in DMEM (Invitrogen) supplemented with 10% fetal calf serum 
(FCS). COS cells were co-transfected with 10 µg pcDNA3.1(+) cystatin C and 10 µg 
pcDNA3.1(-)cathepsin D vector. Cells were transiently transfected using 
Lipofectamine and Opti-MEM (Gibco-BRL). The conditioned media collected two 
days post-transfection were incubated overnight at 4°C with: 3 µg anti-cathepsin D 
M1G8 monoclonal antibody (8), or MOPC21 control monoclonal antibody (Abcam), or 
3 µg anti-cystatin C rabbit polyclonal antibody (DAKO), or control rabbit IgG (R&D 
Systems), and then with 25 µl of 10% protein A-Sepharose, for 2 h at 4°C on a 
shaker. The Sepharose beads were washed 4 times with DMEM, boiled for 3 min in 
SDS sample buffer, and analysed by SDS-PAGE and immunoblotting using the anti-
human cathepsin D monoclonal antibody (BD Biosciences) or anti-cystatin C rabbit 
polyclonal antibody as previously described (7, 8). Procathepsin D was purified from 
medium in which NIH-3T3 cells stably transfected with human cathepsin D or MCF-7 
breast cancer cells had been incubated for 24 h in DMEM without FCS. These 
conditioned media were then passed through an anti-cathepsin D M1G8-coupled 
agarose column. The column was washed with 20 ml of 0.5 M phosphate buffer (pH 
7), 0.15 M NaCl, 0.01% Tween 20, 80.5 mM -glycerophosphate containing protease 
inhibitor cocktail (Complete; Roche Applied Science), and then eluted with a 20 mM 
lysine solution (pH 11). Cystatin C eluted together with procathepsin D was analyzed 




Cleavage of cystatin C by cathepsin D in vitro 
Recombinant procathepsin D (2 µg) (R&D Systems) was auto-activated for 1 h at 
37°C in 50 µl of 0.I M Na-acetate buffer (pH 3.5), 0.2 M NaCl. An aliquot (15 µg) of 
recombinant cystatin C (Abcam) was incubated with 25 µl cathepsin D (1 µg) 
overnight at 37°C at pH 3.5. The cathepsin D had been auto-activated in 0.I M Na-
acetate buffer (pH 3.5) 0.2 M NaCl, with or without pepstatin A (2 µM) (Sigma) in a 
volume of 200 µl. Cleaved peptides were resolved by reverse-phase HPLC on a C8 
column eluted with an acetonitrile gradient in 0.075% trifluoroacetic acid, and NH2-
terminal sequence analysis performed by automatic Edman degradation on a Procise 
sequencer (492 Protein Sequencer, Applied Biosystem). Phosphatidylcholine (Sigma; 
0.12 mM) and cardiolipin (Sigma; 0.05 mM) were added in the reaction mixture for 
cleavage performed at higher pH according to (23).  
 
Degradation of extracellular cystatin C by secreted procathepsin D  
Conditioned medium from MCF-7 cells was obtained by incubating cells for 24 h in 
DMEM without sodium bicarbonate buffered with 50 mM Hepes buffer (pH 7) in 
absence of FCS. The 24 h conditioned medium was then incubated, with or without 
pepstatin A (50 µM), at 37°C at pH 3.5 by acidification with 1N HCl, for up to 3 h. In 
other experiments, the 24 h conditioned medium was incubated, with or without 
pepstatin A (50 µM), at 37°C for 1 h at different pH values using Britton-Robinson 
buffer. The proteins in this treated medium (20 µl) were separated by 17% SDS-





Quantification of cysteine cathepsin activity 
Conditioned media of MCF-7 cells silenced or not for cathepsin D and incubated at 
pH 3.5 for 10 min, or at pH 5.6 for 1 or 2 h were incubated in 100 mM sodium acetate 
buffer (pH 5.5) containing 4 mM DTT, 2 mM EDTA in the presence of Z-Phe-Arg-
AMC (40 μM), and cysteine cathepsin proteolytic activity was monitored continuously 
for 120 min at exc=350 nm and em=460 nm (Gemini spectrofluorimeter, Molecular 
Devices, France). Controls were performed in the presence of the broad-spectrum 
cysteine cathepsin inhibitor, E-64 (10 µM), or the cathepsin B inhibitor, CA-074 (4 
µM).  
 
Immunoblotting of cysteine cathepsins 
The goat anti-human cathepsin S was obtained from R&D Systems (Lille, France). 
Other primary polyclonal antibodies were raised in rabbits: anti-human cathepsin B 
(Calbiochem, VWR International S.A.S., France), anti-human cathepsin L 
(Calbiochem), anti-human cathepsin H (Fitzgerald, Concord, USA). Goat anti-rabbit 
and rabbit anti-goat IgG-peroxidase conjugates were supplied by Sigma-Aldrich. 
Human cathepsins used as control were supplied by Calbiochem. Sample (30 µg)  
from culture medium of MCF-7 cells conditioned for 24 h without FCS and 100 X 
concentrated by passage through Amicon filters to 2 µg/ml was diluted in Laemmli 
buffer under reducing conditions, boiled for 5 min, separated by SDS-PAGE on 15% 
gels (prestained molecular masses: Precision Plus Protein Standards, BioRad) and 
electroblotted onto nitrocellulose membranes. These membranes were incubated 
with the primary antibody (1 µg/ml, in PBS, 0.1% Tween, 5% dried milk for 1 h at 
room temperature), then with the secondary IgG-peroxidase conjugate for 1 h at 
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room temperature. Proteins were detected by chemiluminescence (ECL Plus 
Western Blotting Detection system, Amersham Biosciences, Buckinghamshire, UK). 
 
RESULTS 
Cystatin C binds to procathepsin D secreted by breast cancer cells at neutral 
pH 
We performed a yeast two-hybrid screening using a LexA DNA-binding domain 
fused to the 48-kDa intermediate human cathepsin D as bait, and a cDNA library 
isolated from normal human breast tissue to identify new molecules that interact with 
cathepsin D. The clone we isolated was 100% identical to amino acids 39-146 of 
cystatin C (Fig. 1A). We then verified this interaction by GST pull-down experiments 
with full-length human cystatin C fused to GST (GST-cyst C) (Fig. 1B, panel a). 
Procathepsin D was bound to GST-cyst C (Fig. 1B, panel b), indicating that cystatin 
C interacts directly with procathepsin D.  
Next we then co-transfected COS cells with cystatin C and procathepsin D 
expression vectors to determine whether procathepsin D interacted with cystatin C 
extracellularly. Upon incubation with an anti-cystatin C antibody, analysis of the 
conditioned medium from these cells showed that secreted 52-kDa procathepsin D 
was immunoprecipitated with 14-kDa cystatin C (Fig. 1C, panel a). Reciprocally, 
incubation of the conditioned medium with anti-cathepsin D antibody showed that 
secreted cystatin C was immunoprecipitated along with procathepsin D (Fig. 1C, 
panel b). Thus, the procathepsin D and cystatin C co-transfected in COS cells 
interacted in the extracellular environment at neutral pH.  
We confirmed this extracellular interaction between procathepsin D and cystatin 
C by studying the interaction of procathepsin D with the cystatin C secreted by NIH-
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3T3 fibroblasts stably transfected with cathepsin D at neutral pH. Immunoaffinity 
purification of procathepsin D with an anti-cathepsin D antibody revealed that cystatin 
C copurified with procathepsin D (Fig. 1D, panel a). This indicates that secreted 
cystatin C interacts with the procathepsin D synthesized by stably-transfected NIH-
3T3 fibroblasts at neutral pH.  
We screened cystatin C secretion in a variety of breast cancer cell lines to verify 
the extracellular interaction between procathepsin D and cystatin C (Fig. S1). 
Cathepsin D is known to be over-produced and hypersecreted by breast cancer cells 
(1, 2), and our survey revealed that all the breast cancer cell lines tested, except the 
BT20 cell line, secreted cystatin C (Fig. 1D, panel c). Lastly, since breast cancer cells 
synthesize and secrete procathepsin D and cystatin C, we investigated their 
interaction in the conditioned medium from MCF-7 breast cancer cells at neutral pH. 
Again, cystatin C was purified together with procathepsin D (Fig. 1D, panel b). We 
conclude that cystatin C and procathepsin D interact in secretome of MCF-7 breast 
cancer cells. We have thus shown that procathepsin D interacts directly with cystatin 
C in the extracellular space of breast cancer cells at neutral pH. 
 
Identification of the extracellular proteins affected by a cathepsin D deficiency 
We analysed the secreted proteome harvested from cathepsin D-/- MEFs stably 
transfected with empty vector (CD55-/-SV40) or human cathepsin D (CD55-/- cath-D) 
vector by TAILS at neutral pH to determine the impact of cathepsin D on extracellular 
protein processing. We identified 746 unique N-terminal peptides from 569 unique 
proteins, and quantified 710 of the N-termini from 542 proteins (Fig. 2A). A threefold 
change was used as cut-off to determine N-termini substantially affected by 
cathepsin D activity, as in earlier TAILS studies (19, 24). Based on this criterion, 22 
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neo-N termini were more abundant in cells producing cathepsin D than in cells 
transfected with the empty vector, while 48 mature protein N termini were reduced in 
abundance in the secretome of cathepsin D-transfected cells, indicating cleavage 
and loss of the peptide from cleaved or degraded protein (Table S1).  
Notably,the N-terminus of mature cystatin C was 7-fold less abundant in the 
secretome of cathepsin D transfected cells (CD55-/- cath-D) compared to that of 
cathepsin D deficient cells (CD55-/-SV40) (Table S1). Furthermore, analysis of the 
transcriptome of C55-/-SV40 and C55-/-cath-D cells showed that the reduced cystatin 
C protein in the C55-/-cath-D secretome was not due to down-regulation of cystatin C 
gene expression in the presence of cathepsin D (Fig. 2B, Table S2). Thus, 
proteomics analysis shows that the amount of cystatin C in the extracellular 
environment is reduced in a cathepsin D-dependent manner. 
 
Cleavage of cystatin C by human procathepsin D in vitro 
We investigated the capacity of cathepsin D to cleave cystatin C in vitro at low 
pH. Recombinant 52-kDa human procathepsin D was auto-activated to 51-kDa 
proteolytically active enzyme (Fig. 3, panel a) and then incubated at pH 3.5 with 
recombinant human cystatin C. This resulted in extensive hydrolysis of cystatin C at 
10 major and 3 minor cleavage sites (Fig. 3, panel b). The 10 major sites overlapped 
with the 4 cleavage sites described previously for 34+14-kDa mature human 
cathepsin D (25). Pepstatin A, an inhibitor of aspartic proteases, inhibited the auto-
activation of recombinant procathepsin D (Fig. 3, panel a), and the cleavage of 
cystatin C (data not shown). Thus, procathepsin D degrades cystatin C in an acidic 




Degradation of cystatin C by cathepsin D secreted by breast cancer cells at 
acidic pH 
Since the extracellular environment of tumors is acidic, we examined the 
capacity of procathepsin D interacting extracellularly with cystatin C to degrade it in 
the extracellular medium of breast cancer cells at low pH (Fig. 4). The 52-kDa 
procathepsin D secreted in the conditioned medium of MCF-7 breast cancer cells 
was auto-activated into the 51-kDa proteolytically-active form at low pH (Fig. 4A, 
panel a), as was the recombinant purified procathepsin D (Fig. 3, panel a). Cystatin C 
was hydrolysed in a time-dependent manner in the conditioned medium of MCF-7 
breast cancer cells (Fig. 4A, panel b). Pepstatin A blocked cystatin C degradation, 
confirming the involvement of secreted aspartic protease proteolytic activity (Fig. 4A, 
panel b).  
We then assessed the capacity of procathepsin D to hydrolyse cystatin C at the 
extracellular pH 5.5 to 6.8, found within tumors (Fig. 4B, panel a). The cystatin C 
secreted into the conditioned medium of MCF-7 cells was significantly degraded in a 
pH-dependent manner from pH 3.5 to pH 6.8 (Fig. 4B, panel b). Hydrolysis of 
recombinant cystatin C also occurred with recombinant cathepsin D for acidic pH (3.6 
to 6.2) (Fig. S1). Lastly, we determined whether procathepsin D is the secreted 
aspartic protease responsible for the extracellular breakdown of cystatin C. We 
silenced cathepsin D expression in MCF-7 cells by RNA interference such that no 
extracellular procathepsin D was produced (Fig. 4C, panels a and c). The silencing of 
cathepsin D synthesis led to decreased cystatin C degradation at pH 3.5 (Fig. 4C, 
panel b, bottom) in a time-dependent manner compared to Luc silencing (Fig. 4C, 
panel b, top) Similar results were obtained at pH 5.6 (Fig. 4C, panel d), confirming 
that procathepsin D is the secreted aspartic protease responsible for cystatin C 
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hydrolysis under acidic conditions. Our findings therefore strongly suggest that the 
procathepsin D secreted by breast cancer cells breaks-down cystatin C in the acidic 
breast tumor micro-environment.  
 
Cystatin C degradation by procathepsin D led to increased proteolytic activity 
of extracellular cysteine cathepsins in breast cancer cells 
Since cystatin C is an extremely potent extracellular inhibitor of cysteine 
cathepsins, we investigated the effect of the extracellular hydrolysis of cystatin C by 
procathepsin D on the proteolytic activity of the extracellular cysteine cathepsins (Fig. 
5). We silenced cathepsin D synthesis in MCF-7 cells, which decreased the amounts 
of secreted procathepsin D (Fig. 5, panel a), and analysed cystatin C levels (Fig. 5, 
panel b), and cysteine cathepsin proteolytic activity (Fig. 5, panel c) in the 
extracellular medium at acidic pH. The cystatin C in the conditioned medium of 
procathepsin D-secreting Luc-silenced cells was destroyed at pH 3.5 (Fig. 5, panel b, 
lane 1). As a consequence, there was an overall extracellular proteolytic activity of 
cysteine cathepsins (Fig 5, panel c, lane 1). The cystatin C in the conditioned 
medium of cathepsin D-silenced cells was not degraded at pH 3.5 (Fig. 5, panel b, 
lane 3), and the extracellular cysteine cathepsin proteolytic activity of these cells was 
significantly lower by 3-fold (Fig. 5, panel c, lane 3) than that of Luc-transfected cells 
(Fig. 5, panel c, lane 1). In the presence of pepstatin A, the break-down of cystatin C 
in the conditioned medium was abolished (Fig. 5, panel b, lanes 2 and 4), and the 
extracellular cysteine cathepsin proteolytic activity of these cells was significantly 
lower (Fig 5, panel c, lanes 2 and 4), than that of Luc-transfected cells (Fig. 5, panel 
c, lane 1) (active cathepsins  40 nM as determined by E-64 titration).  
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In order to validate the functional relevance of this pathway at a pH that mimics 
the tumor microenvironment, we confirmed that extracellular hydrolysis of cystatin C 
at pH 5.6 in the extracellular medium of MCF-7 cells (Fig. 6, panel a) led to a 
significant increase of extracellular cysteine cathepsin proteolytic activity (Fig. 6, 
panel b). Among the different cysteine cathepsins detected in the conditioned 
medium of MCF-7 cells, we observed mainly mature cathepsin B (both single-chain 
and double-chain forms) whereas aminopeptidase cathepsin H, and cathepsins L, S 
and K were predominantly detected under their inactive pro-form (Figure 6, panel c). 
CA-074 blocked ~60% of the proteolytic activity towards Z-Phe-Arg-AMC, indicating 
that the majority of this activity was due to cathepsin B (data not shown). We 
therefore conclude that secreted cathepsin D degrades cystatin C in an acidic 
environment, leading to increased proteolytic activity of extracellular cysteine 
cathepsins, such as cathepsin B in particular (Fig. 7). 
 
DISCUSSION 
We show that cystatin C is both bound to procathepsin D secreted by breast 
cancer cells and is a substrate of the enzyme in the extracellular environment at a pH 
not normally associated with cathepsin D activity. Cystatin C is the most potent 
extracellular endogenous inhibitor of the cysteine cathepsins (15) inhibiting the 
growth and metastasis of many tumors (16, 26-28). Several studies have suggested 
the therapeutic use of cystatin C and cysteine cathepsin inhibitors (26, 29-31). 
Cysteine cathepsins, such as cathepsin B and cathepsin L, are frequently miss-
regulated in human cancers, and have been implicated in angiogenesis, proliferation, 
apoptosis, invasion and metastasis (15, 32). Cysteine cathepsins are secreted into 
the extracellular milieu during cancer progression, where they take part in a vast 
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multidimensional network of proteolytic interactions involving metalloproteases and 
serine proteases, rather than simply functioning individually (17, 33). The complexity 
of the proteolytic activation cascade is enhanced by the presence of endogenous 
inhibitors specific for each class of proteases (16, 17). Here, we have demonstrated 
that the procathepsin D secreted by breast cancer cells interacts extracellularly with 
cystatin C in secretome at neutral pH.  
Secreted procathepsin D has been previously described to act as an 
extracellular binding protein in breast cancer, for example the low-density lipoprotein 
receptor-related protein-1 (LRP1) is a novel cathepsin D receptor on fibroblasts (8, 
34). Moreover, interaction of secreted prosaponin and procathepsin D also occurred 
in the breast cancer cell culture medium (35). Our TAILS experiments performed with 
the secretomes of cath-D-/-MEFs stably transfected with human cathepsin D or an 
empty vector showed that the amount of mature cystatin C in the extracellular 
environment was reduced in a cathepsin D-dependent manner, suggesting that 
cystatin C is a physiological substrate for cathepsin D. Earlier proteomic studies have 
shown that cystatin C is also a substrate of matrix metalloproteinase 2 (MMP-2), 
being specifically inactivated upon one cleavage, so highlighting the complexity of the 
proteolytic cascades that are operating in the tumor microenvironment (36).  
We have now shown that procathepsin D extensively cleaves cystatin C in an 
acidic environment in vitro. The main peptide bonds cleaved by cathepsin D at low 
pH are Phe-Phe, Leu-Tyr, Tyr-Leu, and Phe-Tyr (37), which agrees well with the 
cleavage sites identified in the present study. Notably, the sensitivity of the 
proteomics approach used meant that other cleavage sites were also detected. 
Previous studies have shown that mature 34+14-kDa human cathepsin D inactivates 
in vitro at acidic pH different members of the cystatin family, such as stefin A, stefin B 
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and cystatin C (25, 38). It was described that 34+14-kDa human cathepsin D cleaves 
human cystatin C into five fragments in vitro (25), but this cleavage has never been 
previously demonstrated to occur ex cellulo. The procathepsin D cleavage sites we 
identified overlap those previously reported in other systems (25). Our findings 
indicate that the break-down of cystatin C by procathepsin D also occurs in the 
conditioned medium of MCF-7 breast cancer cells in an acidic environment (pH 5.5 to 
6.8), very like that frequently found in tumors due to the production of excess acid in 
hypoxic cells (12, 13, 39). More recently, it was shown that cystatin C is a proteolytic 
target of cathepsin D in the commitment of hematopoietic stem cells to dendritic cells, 
indicating the relevance of this mechanism in other biological processes (40).  
In the present study, we describe an increase in the proteolytic activity of the 
cysteine cathepsins in the acidic conditioned medium of MCF-7 breast cancer cells 
that paralleled the hydrolysis of cystatin C by procathepsin D. Among the different 
cysteine cathepsins detected in the conditioned medium of MCF-7 cells, we observed 
mainly mature proteolytically active cathepsin B whereas aminopeptidase cathepsin 
H and cathepsins L, S and K were detected as proenzymes. It has been suggested 
that secreted procathepsin D directly activates the secreted procathepsin B in an 
acidic environment, converting it into its mature active form (41). In this report, we 
confirmed that cathepsin B was well found mainly in mature form. Moreover, recent 
studies have indicated that the cysteine cathepsin-dependent invasiveness of tumors 
is linked to their proteolytic activity, and is enhanced in an acidic micro-environment 
(42-44). Our present findings strongly suggest that the procathepsin D secreted by 
breast cancer cells is part of the protease web of the tumor acidic micro-environment, 
destroying cystatin C and so increasing cysteine cathepsin proteolytic activity, such 




This novel influence of secreted procathepsin D on the steady-state 
concentration of cystatin C may be crucial for tumor progression and metastasis. 
Elucidating the networks of enzymatic activities that contribute to overall proteolysis 
during carcinogenesis may identify rate-limiting steps or pathways that could be 
targeted by anti-cancer treatment. 
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Figure 1. Binding of cystatin C to procathepsin D secreted by breast cancer 
cells at neutral pH 
(A) Sequence of cystatin C interacting with procathepsin D. Human cystatin C is 
synthesized as a 146-amino-acid protein. The signal peptide (residues 1-26) is 
shown in italic. Residues 39-146, isolated by the yeast two-hybrid method, are 
underlined. 
(B) Binding of procathepsin D to cystatin C by GST pull-down. Radio-labeled 
human procathepsin D synthesized in the reticulocyte lysate system was incubated 
with glutathione-Sepharose beads containing GST-cystatin C (GST-Cyst C) or GST 
alone. GST proteins were stained with Coomassie (panel a), and bound procathepsin 
D was detected by autoradiography (panel b). The input corresponds to the lysate 
used for the binding reaction.  
(C) Extracellular interaction of transfected procathepsin D and cystatin C. COS 
cells were transiently co-transfected with the expression vectors for human cystatin C 
and cathepsin D and the conditioned medium was obtained 48 h post-transfection. 
Panel a: the conditioned medium was immunoprecipitated with anti-cathepsin D 
M1G8 monoclonal, anti-cystatin C rabbit polyclonal, and control rabbit polyclonal 
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(IgG) antibodies. Panel b: immunoprecipitations with anti-cathepsin D M1G8 
monoclonal, anti-cystatin C polyclonal, and MOPC monoclonal antibodies. 
Conditioned medium (CM) (100 µl), and cathepsin D, cystatin C and control (IgG or 
MOPC) immunoprecipitates (IP) were analyzed by anti-cathepsin D (panel a) and 
anti-cystatin C (panel b) immunoblotting. Arrows show co-immunoprecipitates of 
procathepsin D and cystatin C. 
(D) Co-purification of secreted procathepsin D and cystatin C. Cystatin C was 
co-purified with procathepsin D in the extracellular culture medium of cathepsin D-
transfected NIH-3T3 fibroblasts (panel a) and in MCF-7 cells (panel b). Cells grown to 
90% confluence were incubated for 24 h in serum-free medium and this conditioned 
medium was loaded onto an anti-cathepsin D M1G8 affinity column. The eluted 
fraction (EF) corresponding to 2 µg of purified procathepsin D and conditioned 
medium were analysed by anti-cystatin C immunoblotting. Arrows show cystatin C 
co-purified with procathepsin D. Cystatin C secretion was analysed in the conditioned 
media of cancer cells maintained in DMEM with 10% FCS for 24 h by anti-cystatin C 
immunoblotting (panel c). NS, non-specific band showing sample loading. 
 
Figure 2. Cystatin analysis in cath-D-/- MEFs transfected with cathepsin D 
(A) Identification of protein termini affected by cathepsin D deficiency by TAILS 
Comparison of the amounts of identified protein N-termini in the secretomes of 
cathepsin D deficient murine cells expressing human cathepsin D (CD55-/-cath-D) 
and of cells transfected with empty vector (control, CD55-/-SV40) is presented. The 
distribution of the ratios of cathepsin D expressing cells versus control (log2) among 
the identified N-termini in secretomes is shown. Protein termini whose amount 
changed more than 3-fold (log2 above 1.58 or below -1.58, highlighted in light grey) 
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were considered severely affected. An arrow indicates the bin in which the mature N-
terminus of murine cystatin C was found. 
(B) Identification of mRNAs affected by cathepsin D deficiency by 
transcriptomic analysis 
Distribution of the expression values (in log2 of ratio) between CD55-/-cath-D and 
CD55-/-SV40 as boxplot, one for each replicate is shown. Expression values for 
cystatin C are represented by a diamond (values of 1.51 and 1.42), respectively. 
Conventional threshold (Fold-change >= 2 or <= -2, i.e log2(R) >= 1 or <= -1) was 
used to consider a gene as over- (respectively under-) expressed is shown as 
dashed line. 
 
Figure 3. Cleavage of cystatin C by 52-kDa procathepsin D auto-activated to 
proteolytically-active 51-kDa enzyme at acidic pH 
Panel a: recombinant 52-kDa procathepsin D was auto-activated to proteolytically-
active 51-kDa cathepsin D by incubation at pH 3.5 for 1 h. It was then incubated with 
recombinant cystatin C at pH 3.5 with or without pepstatin A. Panel b: sites of cystatin 
C cleavage by proteolytically-active 51-kDa cathepsin D at low pH. Cleaved cystatin 
C peptides were separated by reverse-phase HPLC and subjected to NH2-terminal 
sequence analysis. (), major sites cleaved by 51-kDa cathepsin D; (->), minor sites 
cleaved by 51-kDa cathepsin D; *, published cleavage sites of 34+14-kDa mature 
cathepsin D (25).  
 
Figure 4. Degradation of cystatin C by procathepsin D secreted by breast 
cancer cells at acidic pH 
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(A) Time-course of cystatin C degradation in MCF-7 cells. Cells were incubated 
for 24 h in FCS-free DMEM without sodium bicarbonate buffered with 50 mM Hepes, 
pH 7. The 24 h conditioned medium was then incubated, with or without pepstatin A 
(50 µM), at 37°C at pH 3.5 by acidification with 1N HCl, for up to 180 min. 
Conditioned medium was analysed by anti-cathepsin D and anti-cystatin C 
immunoblotting. Panel a: 52-kDa procathepsin D auto-activated to 51-kDa cathepsin 
D in the acidic conditioned medium at 30 min in the absence of pepstatin A. Panel b: 
breakdown of cystatin C in the absence of pepstatin A. 
(B) Influence of acidity on cystatin C degradation in MCF-7 cells. Cells were 
incubated for 24 h in DMEM without sodium bicarbonate buffered with 50 mM Hepes, 
pH 7. The conditioned medium was then incubated at the indicated pH using Britton-
Robinson buffer for 1 h with or without pepstatin A (50 µM). Panel a: conditioned 
medium subjected to SDS-PAGE and anti-cystatin C immunoblotting. Panel b: mean 
± SD (3 independent experiments). P<0.05 versus cystatin level in presence of 
pepstatin A for each pH (Student’s t-test). 
(C) Hydrolysis of cystatin C by procathepsin D secreted by MCF-7 cells. MCF-7 
cells were transfected with Luc or cathepsin D siRNAs. 48 h-post-transfection, the 
culture medium was changed and conditioned media were prepared by incubating 
the siRNA-transfected cells in FCS-free DMEM without sodium bicarbonate buffered 
with 50 mM Hepes pH 7 for 24 h. Panels a and c: the procathepsin D and cystatin C 
secreted into the conditioned medium of cells transfected with Luc or cathepsin D 
siRNAs assessed by immunoblotting. Panel b: the conditioned media of cells 
transfected with Luc or cathepsin D siRNAs were then incubated at pH 3.5 for the 
indicated times with or without pepstatin A, and analysed by SDS-PAGE and anti-
cystatin C immunoblotting. Panel d: the conditioned media of cells transfected with 
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Luc or cathepsin D siRNAs were then incubated at pH 5.6 for 2 h with or without 
pepstatin A, and analysed as in panel b.  
 
Figure 5. Cystatin C degradation by procathepsin D led to increased proteolytic 
activity of the extracellular cysteine cathepsins in breast cancer cells at pH 3.5 
MCF-7 cells were transfected with Luc or cathepsin D siRNAs. 48 h-post-transfection, 
DMEM medium without sodium bicarbonate buffered with 50 mM Hepes (pH 7) was 
added and the cells were incubated for a further 24 h in the absence of serum. Panel 
a: the procathepsin D and cystatin C secreted into the conditioned medium of cells 
transfected with Luc or cathepsin D siRNAs assessed by immunoblotting. Panel b: 
the conditioned media obtained from the siRNA-transfected cells secreting 
procathepsin D and Luc controls were incubated at pH 3.5 for 10 min with or without 
pepstatin A (50 µM). The cystatin C in the four corresponding conditioned media was 
analysed by SDS-PAGE and anti-cystatin C immunoblotting (lanes 1-4). Panel c: 
cysteine cathepsin proteolytic activity in the four conditioned media (lanes 1-4) 
(quadruplicate analysis). Means ± SD are shown. P<0.005 versus lane 1 (Student’s t-
test). 
 
Figure 6. Cystatin C degradation led to increased proteolytic activity of the 
extracellular cysteine cathepsins in breast cancer cells at pH 5.6 
Panel a: the conditioned medium obtained from MCF-7 cells was incubated at pH 5.6 
for 1 or 2 h with or without pepstatin A (50 µM). The cystatin C in the four 
corresponding conditioned media was analysed by SDS-PAGE and anti-cystatin C 
immunoblotting. Panel b: cysteine cathepsin proteolytic activity in the four 
corresponding conditioned media. Mean values ± SD from 6 measurements are 
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shown. P<0.005 versus cysteine cathepsin proteolytic activity at 1 h in absence of 
pepstatin A (Student’s t-test). Panel c: Detection of cathepsins B, H, L, K and S in the 
conditioned medium (CM) of MCF-7 cells by immunoblotting. Mature cathepsins B, H, 
L, K and S were used as control. *, proform; < mature form. 
 
Figure 7. Model of cystatin C inactivation by procathepsin D in the tumor 
microenvironment of cancers cells  
We propose that procathepsin D secreted in excess by cancer cells degrades 
cystatin C, thereby leading to an increased extracellular proteolytic activity of cysteine 
cathepsins, such as cathepsin B in particular. The procathepsin D secreted by breast 
cancer cells is therefore a new component of tumor progression that triggers the 
proteolytic networks by inactivating cystatin C. 
 
 
